Abstract
Residual disease (RD) after induction chemotherapy may predict clinical outcome in acute myeloid leukemia (AML). In the present study, we investigated the prognostic significance of RD detected by multidimensional flow cytometry (MDF) among 34 children treated for AML in a clinical trial (JPLSG AML-05) in Japan. Bone marrow samples were analyzed at the points of the end of the first induction course (BMA-1) and second induction course (BMA-2) by MDF. RD was evaluated by detecting the immature cells showing abnormal antigen expression pattern; CD34(+), CD15(+), CD7(+). Thirteen (39.4 %) of 34 patients at BMA-1 and 8 (27.6 %) of 34 at BMA-2 had RD levels ≥0.1 %. There was no significant difference in 3y-EFS and 3y-OS between patients with RD levels ≥0.1 % and those with RD levels <0.1 % (53.8 versus 70.0 %, P = 0.30 and 50.0 versus 66.7 %, P = 0.27, respectively). However, IR cytogenetics and negative FLT3-ITD patients with RD levels ≥0.1 % exhibited significantly lower 3y-EFS and 3y-OS than those with RD levels <0.1 % (33.3 versus 83.3 %, P = 0.02 and 20.0 versus 76.9 %, P = 0.005, respectively). Our study suggests that RD shows prognostic relevance in pediatric patients with IR cytogenetics and negative FLT3-ITD AML.
References
Nov 1, 1993·American Journal of Clinical Pathology·M J BorowitzG T Stelzer
Mar 20, 1993·Annals of the New York Academy of Sciences·G T StelzerM R Loken
Dec 31, 2002·Blood·Eric L SieversMichael R Loken
Mar 22, 2003·Blood·Denise A WellsH Joachim Deeg
Oct 9, 2003·British Journal of Haematology·Elaine Coustan-SmithDario Campana
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jun 18, 2004·Leukemia·N FellerG J Schuurhuis
Nov 24, 2005·Leukemia·B E S GibsonC J Harrison
Aug 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN MRD-AML-BFM Study GroupDirk Reinhardt
Aug 17, 2006·Blood·Soheil MeshinchiJerald P Radich
Sep 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ursula CreutzigDirk Reinhardt
Jun 20, 2007·Leukemia Research·Michael R LokenDenise A Wells
Nov 15, 2007·Blood·Beverly J LangeTodd A Alonzo
Jul 22, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ichiro TsukimotoRyoji Hanada
May 11, 2010·The Lancet Oncology·Jeffrey E RubnitzDario Campana
Jul 30, 2010·Leukemia·V H J van der VeldenJ J M van Dongen
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jonas AbrahamssonHenrik Hasle
Dec 24, 2010·JAMA : the Journal of the American Medical Association·Andrew J GentlesAsh A Alizadeh
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ching-Hon PuiRobert J Arceci
Mar 10, 2011·British Journal of Haematology·Gert J OssenkoppeleGerrit Jan Schuurhuis
Jan 13, 2012·Nature·Li DingJohn F DiPersio
May 4, 2012·Leukemia Research·Takuya MiyazakiYoshiaki Ishigatsubo
Jun 1, 2012·Blood·Michael R LokenSoheil Meshinchi
Sep 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hiroto InabaDario Campana
May 17, 2013·Leukemia·D TomizawaS Adachi
Jul 23, 2014·Blood·David Grimwade, Sylvie D Freeman
Sep 23, 2014·Expert Review of Hematology·Rolf WoutersJacqueline Cloos